Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Short Interest Down 20.4% in January

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) was the target of a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 69,500 shares, a drop of 20.4% from the December 31st total of 87,300 shares. Currently, 10.1% of the company’s shares are sold short. Based on an average daily trading volume, of 99,900 shares, the days-to-cover ratio is currently 0.7 days.

Qualigen Therapeutics Trading Down 3.8 %

Shares of Qualigen Therapeutics stock opened at $3.27 on Friday. The business’s fifty day moving average price is $4.18 and its 200 day moving average price is $7.03. Qualigen Therapeutics has a twelve month low of $2.96 and a twelve month high of $29.43.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.